Funding news
DotBio logo

DotBio Raises $5.6M Series A Funding

Recently funded · $5.6M Series aHospitals and Health CareSGView source

Get the full DotBio company profile

Access contacts, investors, buying signals & more

Open in Dashboard

DotBio, a biotech firm focused on developing novel immuno-oncology drugs, has closed its Series A funding round, securing $5.6M. The company leverages its proprietary DotBody technology to create multi-specific, humanized, and highly-stable domain therapeutic antibodies.

This innovative approach was conceptualized by founders Professor Pär Nordlund and Dr. Ignacio Asial. Their expertise in protein and antibody engineering, developed at Singapore’s Nanyang Technological University, underpins the DotBody technology.

Other Singapore companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
Illumina logo

Illumina

United States

$7.1B
4
GRAIL logo

GRAIL

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series a rounds

Companies that recently closed a Series a round.

#CompanyAmount
1
DV Labs logo

DV Labs

United States

$12.5M
2
Edge logo

Edge

United States

$530.0K
3
POIZON  Global logo

POIZON Global

Hong Kong

$50.0M
4
Xverse logo

Xverse

Hong Kong

$80.0M
5
Verta logo

Verta

United States

$10.0M